TransMedics Group (TMDX)
(Delayed Data from NSDQ)
$85.98 USD
+0.48 (0.56%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $85.99 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$85.98 USD
+0.48 (0.56%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $85.99 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Zacks News
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
TransMedics (TMDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will TransMedics (TMDX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Maxar (MAXR) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Maxar's (MAXR) fourth-quarter performance is likely to have benefited from growth in the Imagery and Services segment.
TransMedics' OCS Technology Sees Success in Heart Transplant
by Zacks Equity Research
TransMedics (TMDX) successfully completes heart transplants from DCD donors, using its OCS technology.